Spain’s Supreme Court opines on Pfizer dual pricing contracts

The Spanish Supreme Court has reviewed a ruling adopted by the Audiencia Nacional, itself annulling a decision of the Spanish Competition Authority, which declared that dual pricing contracts implemented by US pharma giant Pfizer (NYSE: PFE) did not infringe European Union competition rules.

The Supreme Court has rejected the appeals of Pfizer and the Spanish Competition Authority, ruling the decision of Spanish Competition Authority null and void.

According to a posting on the European Association of Euro-Pharmaceutical companies (EAEPC), the principles established by the Supreme Court are as follows: